This piece was updated to change the drug type of KB109 from “live biotherapeutic product” to “synthetic polymer.”
As of December 2020, an estimated 36 new nontraditional products with the potential to treat or prevent serious bacterial infections were in clinical development.
The below interactive resource—based on publicly available information and informed by external experts and company communication—focuses on the nontraditional products currently in the clinical development pipeline. To view subsets of products, use filter options below or click on corresponding sections of the pie charts.
Please contact [email protected] with additions or updates.
For definitions of drug development terms and nontraditional product types, visit https://www.pewtrusts.org/en/research-and-analysis/articles/2014/03/12/glossary-for-the-antibiotic-pipeline .
See the methodology section for further details.
Note: The following drugs have been removed from the pipeline. Removed candidates will be included in future updates if development resumes:
A collection of resources to help federal, state, and local decision-makers set an achievable agenda for all Americans
Data-driven state policy innovations across America